Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4489-4500
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4489
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4489
Table 1 Demographic and pathological characteristics
Characteristics | siTP group (n = 13) | seTP group (n = 17) | PVE-only group (n = 21) | P value |
Male, n (%) | 10 (77) | 13 (76) | 17 (81) | 0.935 |
Age (yr) | 51.5 ± 10.0 | 54.0 ± 11.2 | 59.2 ± 8.3 | 0.068 |
Etiology, n (%) | 0.928 | |||
HBV | 9 (69) | 12 (70) | 15 (71) | |
Alcoholic | 1 (8) | 2 (12) | 2 (10) | |
NASH | 3 (23) | 3 (18) | 3 (14) | |
Schistosomiasis | 0 | 0 | 1 (5) | |
ECOG performance status, n (%) | 0.725 | |||
0 | 10 (77) | 13 (76) | 18 (86) | |
1 | 3 (23) | 4 (24) | 3 (14) | |
Tumor multiplicity, n (%) | 0.809 | |||
Single | 11 (85) | 14 (82) | 15 (71) | |
Multiple | 2 (15) | 3 (18) | 6 (29) | |
Tumor size (cm) | 8.4 ± 2.7 | 8.3 ± 2.3 | 7.7 ± 1.9 | 0.630 |
ICGR15 (%) | 5.7 ± 3.0 | 5.0 ± 2.6 | 6.0 ± 2.7 | 0.511 |
Baseline FLR (%) | 31.2 ± 3.7 | 31.8 ± 4.5 | 33.2 ± 3.5 | 0.150 |
AFP (ng/mL) | 377 (11-3419) | 487 (16-12000) | 551 (9-10344) | 0.640 |
ALT (U/mL) | 30.2 ± 13.8 | 40.5 ± 26.0 | 40.4 ± 24.0 | 0.380 |
AST (U/mL) | 39.5 ± 16.2 | 58.2 ± 40.0 | 49.5 ± 20.8 | 0.212 |
TBIL (μg/mL) | 19.0 ± 5.1 | 17.4 ± 5.2 | 21.2 ± 6.9 | 0.147 |
Table 2 Outcomes after portal vein embolization with or without transarterial chemoembolization and before hepatectomy
Variable | siTP group (n = 13) | seTP group (n = 17) | PVE-only group (n = 21) | P value |
FLR (%) (before hepatectomy) | 45.9 ± 4.2 | 43.3 ± 6.6 | 43.0 ± 4.7 | 0.262 |
Interval from TACE/PVE to hepatectomy | 16.2 ± 2.7 | 37.9 ± 6.5 | 35.4 ± 10.6 | < 0.001 |
KGR (%) | 21.1 ± 5.9 | 7.6 ± 2.9 | 6.8 ± 3.6 | < 0.001 |
Tumor size reduction, n (%) | 13 (100) | 13 (76) | 2 (10) | < 0.001 |
Complications, n (%) | 0.875 | |||
Abdominal pain | 6 (46) | 9 (53) | 3 (14) | |
Fever | 7 (54) | 8 (47) | 3 (14) | |
Nausea | 2 (15) | 4 (24) | 2 (10) | |
Acute pulmonary infarction | 0 | 1 (6) | 0 |
Table 3 Introperative and postoperative outcomes of three groups
Variables | siTP group (n = 13) | seTP group (n = 17) | PVE-only group (n = 21) | P value |
Patients with major hepatectomy, n (%) | 13 (100) | 14 (82) | 14 (67) | 0.057 |
Surgical approach, n (%) | 0.868 | |||
Right hemihepatectomy | 9 (69) | 12 (71) | 9 (43) | |
Right hepatic trisegmentectomy | 2 (15) | 1 (6) | 3 (14) | |
Left hemihepatectomy | 1 (8) | 0 | 1 (5) | |
Left hepatic trisegmentectomy | 1 (8) | 1 (6) | 1 (5) | |
Operation time (min) | 261.4 ± 51.8 | 210.7 ± 53.7 | 246.1 ± 66.4 | 0.080 |
Intraoperative blood loss (mL) | 285.0 ± 138.7 | 265.7 ± 153.6 | 343.9 ± 136.7 | 0.266 |
Transfusion, n (%) | 4 (31) | 4 (29) | 2 (10) | 0.550 |
Hospital stay after surgery (d) | 10.9 ± 2.1 | 11.9 ± 3.9 | 12.3 ± 3.4 | 0.503 |
Complications, n (%) | 0.842 | |||
Liver failure | 1 (8) | 0 | 2 (10) | |
Bilirary fistula | 3 (23) | 4 (24) | 2 (10) | |
Hydroperitonium | 1 (8) | 2 (12) | 0 | |
Hydrothorax | 2 (15) | 1 (6) | 1 (5) | |
Abdominal infection | 2 (15) | 1 (6) | 1 (5) | |
Perioperative death, n (%) | 0 | 0 | 1 (5) | 0.372 |
Pathologic response, n (%) | < 0.001 | |||
MPR (RT < 10%) | 6 (46) | 2 (12) | 0 | |
PPR (RT from 10% to 50%) | 3 (23) | 2 (12) | 0 |
- Citation: Zhang CW, Dou CW, Zhang XL, Liu XQ, Huang DS, Hu ZM, Liu J. Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy. World J Gastroenterol 2020; 26(30): 4489-4500
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4489.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4489